Whitehawk Net Interest Income from 2010 to 2026
| WHWK Stock | 2.70 0.08 2.88% |
Net Interest Income | First Reported 2010-12-31 | Previous Quarter 4.3 M | Current Value 2.4 M | Quarterly Volatility 2.3 M |
Check Whitehawk Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Whitehawk Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.5 K, Interest Expense of 131.7 K or Selling General Administrative of 26.4 M, as well as many indicators such as Price To Sales Ratio of 3.59, Dividend Yield of 0.0165 or PTB Ratio of 1.54. Whitehawk financial statements analysis is a perfect complement when working with Whitehawk Therapeutics Valuation or Volatility modules.
Whitehawk | Net Interest Income | Build AI portfolio with Whitehawk Stock |
Latest Whitehawk Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Whitehawk Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Whitehawk Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Whitehawk Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Whitehawk Net Interest Income Regression Statistics
| Arithmetic Mean | 566,394 | |
| Geometric Mean | 1,192,753 | |
| Coefficient Of Variation | 401.80 | |
| Mean Deviation | 1,877,967 | |
| Median | (774,000) | |
| Standard Deviation | 2,275,793 | |
| Sample Variance | 5.2T | |
| Range | 6.9M | |
| R-Value | 0.73 | |
| Mean Square Error | 2.6T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | 330,603 | |
| Total Sum of Squares | 82.9T |
Whitehawk Net Interest Income History
About Whitehawk Therapeutics Financial Statements
Whitehawk Therapeutics investors utilize fundamental indicators, such as Net Interest Income, to predict how Whitehawk Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 4.3 M | 2.4 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Whitehawk Therapeutics Correlation against competitors. For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. If investors know Whitehawk will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Whitehawk Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
The market value of Whitehawk Therapeutics is measured differently than its book value, which is the value of Whitehawk that is recorded on the company's balance sheet. Investors also form their own opinion of Whitehawk Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Whitehawk Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Whitehawk Therapeutics' market value can be influenced by many factors that don't directly affect Whitehawk Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Whitehawk Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.